Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418626 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00418626 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT00418626, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will be a formal assessment of the impact of hepatic function impairment on the pharmacokinetics of nilotinib
Interventions
- DRUG Nilotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00418626
The ClinicalTrials.gov registry entry for NCT00418626 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nilotinib is the first listed.
NCT00418626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00418626 about?
NCT00418626 is a clinical study titled "Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function". This study will be a formal assessment of the impact of hepatic function impairment on the pharmacokinetics of nilotinib
What is the current status of trial NCT00418626?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2006-11.
What interventions are being tested in trial NCT00418626?
The interventions under investigation include: Nilotinib (DRUG).
Who is sponsoring clinical trial NCT00418626?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.